Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Tatsushi Yoshida
  • Toshiyuki Sakai
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6065-2


Tunicamycin is an antibiotic identified and isolated from the fermentation broth of Streptomyces lysosuperificus. Since the antibiotic interferes with the formation of viral and cellular surface coats, it was termed “tunicamycin” after the Latin word “tunica” for coats.


Structure and Function

Tunicamycin is a nucleoside antibiotic composed of uracil, a fatty acid, and two glycosidically linked sugars. The sugars are N-acetylglucosamine and an unusual 11-carbon aminodeoxydialdose, which has been named tunicamine. Tunicamycin is a white crystalline powder which is soluble in alkaline water, pyridine, and hot methanol; slightly soluble in ethanol and n-butanol; and insoluble in acetone, ethylacetate, chloroform, benzene, and acidic water. High-performance liquid chromatography (HPLC) of tunicamycin shows that the antibiotic is separated into ten different components that have molecular weights ranging from 802 to 858. These differences in molecular mass are...


Endoplasmic Reticulum Stress Unfold Protein Response Newcastle Disease Virus Mouse Embryonic Fibroblast Endoplasmic Reticulum Kinase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Eibein AD (1987) Inhibition of the biosynthesis and processing of N-linked oligosaccharide chains. Ann Rev Biochem 56:497–534CrossRefGoogle Scholar
  2. Ma Y, Hendershot LM (2004) The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 4:966–977CrossRefPubMedGoogle Scholar
  3. Noda I, Fujieda S, Seki M et al (1999) Inhibition of N-linked glycosylation by tunicamycin enhances sensitivity to cisplatin in human head-and-neck carcinoma cells. Int J Cancer 80:279–284CrossRefPubMedGoogle Scholar
  4. Shiraishi T, Yoshida T, Nakata S et al (2005) Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res 65:6364–6370CrossRefPubMedGoogle Scholar
  5. Takatsuki A, Tamura G (1982) Inhibition of glycoconjugate biosynthesis by tunicamycin. In: Tamura G (ed) Tunicamycin. Japan Scientific Societies Press, Tokyo, pp 35–70Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical ScienceKyoto Prefectural University of MedicineKyotoJapan